09:24 AM EDT, 09/06/2024 (MT Newswires) -- Y-mAbs Therapeutics ( YMAB ) reported Friday that its cancer drug naxitamab demonstrated consistent disease control in refractory or relapsed high-risk, or hard-to-treat neuroblastoma cancer patients.

The company said naxitamab, combined with granulocyte-macrophage colony-stimulating factor, achieved a 63% disease control rate in patients with refractory or relapsed high-risk neuroblastoma, regardless of their baseline condition.

Y-mAbs also unveiled preclinical findings for its GD2-SADA therapy, which showed potential of delivering targeted radiation to cancer cells.